Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial
5 hours ago
- #Clinical Trial
- #JAK Inhibitor
- #Prurigo Nodularis
- The phase I/II trial evaluated topical 1.5% ruxolitinib gel (HDM3010) for prurigo nodularis in adults.
- HDM3010 showed a favorable safety profile with low systemic exposure and few treatment-related adverse events.
- Efficacy outcomes indicated improvements in itch severity and lesion scores compared to vehicle control.